Published in J Neurol on August 14, 2014
Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clin Res Cardiol (2015) 0.91
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation (2017) 0.82
Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding. J Atr Fibrillation (2015) 0.75
Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Saf (2016) 0.75
Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis. Clin Med Insights Blood Disord (2017) 0.75
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med (2002) 8.72
Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med (2001) 8.17
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Comparison of two methods to detect publication bias in meta-analysis. JAMA (2006) 7.34
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. BMJ (1999) 4.94
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med (1993) 4.66
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 4.43
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circ J (2012) 3.70
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16
Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. Am J Cardiol (2013) 2.16
Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol (2007) 2.02
Meta-analysis of rivaroxaban and bleeding risk. Am J Cardiol (2013) 1.53
Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Crit Care (2013) 1.43
The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS One (2013) 1.32
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ (2012) 0.99
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes (2013) 0.98
Meta-analysis of incidence of rare events. Stat Methods Med Res (2012) 0.98
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98
Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study. BMJ (1999) 0.89
Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. J Thromb Haemost (2010) 0.85
The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery. Pharmacotherapy (2013) 0.79
Clinically useful measures of the effects of treatment. Evid Based Nurs (2001) 0.76
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Safety of chiropractic interventions: a systematic review. Spine (Phila Pa 1976) (2009) 4.03
How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord (2010) 3.60
Chiropractic manipulation: reasons for concern? Clin Neurol Neurosurg (2007) 2.10
Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev (2011) 1.96
Association between red blood cell distribution width and outcomes at six months in patients with acute coronary syndromes. Rev Port Cardiol (2009) 1.53
Spontaneous plugging of the horizontal semicircular canal with reversible canal dysfunction and recovery of vestibular evoked myogenic potentials. Otol Neurotol (2013) 1.51
Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis of observational studies. Heart (2013) 1.49
Quantitative wearable sensors for objective assessment of Parkinson's disease. Mov Disord (2013) 1.47
The role of European national journals in education. Heart (2009) 1.46
Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals. Eur Heart J (2012) 1.42
Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol (2010) 1.41
Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism. Mov Disord (2013) 1.40
European Society of Cardiology national cardiovascular journals: the 'editors' network'. Eur Heart J (2009) 1.31
[European National Society cardiovascular journals. Background, rationale and mission statement of the "editors' club"]. Rev Esp Cardiol (2008) 1.26
Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease. PLoS One (2011) 1.19
Apathy secondary to stroke: a systematic review and meta-analysis. Cerebrovasc Dis (2013) 1.13
Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis (2010) 1.10
Limitations of current Parkinson's disease therapy. Ann Neurol (2003) 1.07
Report on the first written exam held as part of the European Association of Echocardiography accreditation process in adult transthoracic echocardiography. Eur J Echocardiogr (2004) 1.05
Motor Unit Number Index (MUNIX): a novel neurophysiological marker for neuromuscular disorders; test-retest reliability in healthy volunteers. Clin Neurophysiol (2011) 1.05
Putaminal petechial haemorrhage as the cause of non-ketotic hyperglycaemic chorea: a neuropathological case correlated with MRI findings. J Neurol Neurosurg Psychiatry (2007) 1.03
Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev (2015) 0.97
Late-stage Parkinson disease. Nat Rev Neurol (2012) 0.97
Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements. Amyotroph Lateral Scler Other Motor Neuron Disord (2005) 0.96
Paralytic shellfish poisoning due to ingestion of Gymnodinium catenatum contaminated cockles--application of the AOAC HPLC official method. Toxicon (2012) 0.96
Non-compaction cardiomyopathy. Heart (2013) 0.95
Clinical comparability of marketed formulations of botulinum toxin. Mov Disord (2004) 0.95
A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol (2007) 0.94
A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 0.94
Motor Unit Number Index (MUNIX): reference values of five different muscles in healthy subjects from a multi-centre study. Clin Neurophysiol (2011) 0.93
Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts: a systematic review. J Neurosurg Pediatr (2008) 0.93
Coexistence of coronary cameral fistulae and cor triatriatum sinister in an elderly patient. Eur J Echocardiogr (2008) 0.92
Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression. Nat Rev Neurol (2010) 0.92
Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart (2014) 0.91
The placebo response in studies of acute migraine. J Pediatr (2007) 0.91
Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals. Med Arch (2012) 0.91
Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clin Res Cardiol (2015) 0.91
Associated movement disorders in orthostatic tremor. J Neurol Neurosurg Psychiatry (2012) 0.90
Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am J Cardiol (2012) 0.89
Prescribing patterns of antiparkinsonian agents in Europe. Mov Disord (2010) 0.89
Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord (2011) 0.88
Cardiovascular toxicity of cocaine of iatrogenic origin. Case report. Rev Port Cardiol (2007) 0.88
Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family. Arch Neurol (2002) 0.87
Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals. Heart (2012) 0.87
IFNAR1 controls progression to cerebral malaria in children and CD8+ T cell brain pathology in Plasmodium berghei-infected mice. J Immunol (2013) 0.87
Validation of the isovolumetric relaxation time for the estimation of pulmonary systolic arterial blood pressure in chronic pulmonary hypertension. Eur Heart J Cardiovasc Imaging (2012) 0.86
Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat Disord (2008) 0.86
Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2016) 0.86
Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol (2012) 0.85
Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol (2014) 0.85
The burden of disease attributable to smoking in Portugal. Rev Port Pneumol (2009) 0.85
What motivates Parkinson's disease patients to enter clinical trials? Parkinsonism Relat Disord (2011) 0.84
Genotyping with Sequenom. Methods Mol Biol (2011) 0.84
Non-compaction cardiomyopathy: prevalence, prognosis, pathoetiology, genetics, and risk of cardioembolism. Curr Heart Fail Rep (2014) 0.84
The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. Br J Haematol (2013) 0.84
Skin cancers and precancerous lesions in Parkinson's disease patients. Mov Disord (2007) 0.84
Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy. Muscle Nerve (2013) 0.84
Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. J Neural Transm (Vienna) (2014) 0.83
Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals. Rev Port Cardiol (2012) 0.83
Right ventricular function in patients with pulmonary hypertension; the value of myocardial performance index measured by tissue Doppler imaging. Eur J Echocardiogr (2010) 0.83
Non-HLA autoimmunity genetic factors contributing to Autoimmune Polyglandular Syndrome type II in Tunisian patients. Hum Immunol (2012) 0.82
A randomized, rater-blinded, parallel trial of intensive speech therapy in sub-acute post-stroke aphasia: the SP-I-R-IT study. Int J Lang Commun Disord (2013) 0.82
The management of cervical dystonia. Expert Opin Pharmacother (2007) 0.82
The burden of disease and the cost of illness attributable to alcohol drinking--results of a national study. Alcohol Clin Exp Res (2010) 0.81
Branded versus generic clopidogrel in cardiovascular diseases: a systematic review. J Cardiovasc Pharmacol (2013) 0.81
Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. Neurotox Res (2016) 0.81
European National Society Cardiovascular Journals. Background, rationale and mission statement of the "Editors' Club" (Task Force of the European Society of Cardiology). Clin Res Cardiol (2008) 0.80
Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev (2015) 0.80
Ictal singing: case report and reappraisal of the literature. Epileptic Disord (2008) 0.80
Anticonvulsants for preventing seizures in patients with chronic subdural haematoma. Cochrane Database Syst Rev (2013) 0.80
Proximal left anterior descending coronary artery revascularization with drug-eluting stents. Arq Bras Cardiol (2007) 0.79
Cardiopulmonary effects following endoscopic thoracic sympathectomy for primary hyperhidrosis. Eur J Cardiothorac Surg (2009) 0.79
Usefulness of OSLER test in Parkinson's disease. Sleep Med (2012) 0.79
Percutaneous nocturnal oximetry in amyotrophic lateral sclerosis: periodic desaturation. Amyotroph Lateral Scler (2009) 0.79
Skin autonomic reactivity to thermoalgesic stimuli. Clin Auton Res (2007) 0.79
Constructing risk adjustment models for percutaneous coronary intervention: implications for quality assessment. Rev Port Cardiol (2010) 0.78
NOS2 variants reveal a dual genetic control of nitric oxide levels, susceptibility to Plasmodium infection, and cerebral malaria. Infect Immun (2013) 0.78
Prognostic impact of hemoglobin drop during hospital stay in patients with acute coronary syndromes. Rev Port Cardiol (2009) 0.78
Circulating miR-122-5p/miR-133b Ratio Is a Specific Early Prognostic Biomarker in Acute Myocardial Infarction. Circ J (2016) 0.77
GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. Parkinsonism Relat Disord (2009) 0.77
Looking for myocardial viability after a STICH trial: not enough to close the door. J Nucl Med (2012) 0.77
The effects of transcranial magnetic stimulation on vibratory-induced presynaptic inhibition of the soleus H reflex. Exp Brain Res (2012) 0.77
Pharmacotherapy in Parkinson's disease: case studies. Ther Adv Neurol Disord (2010) 0.76
Tolerability and Acceptability of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs (2015) 0.76